Liraglutide
Also known as Victoza, Saxenda, GLP-1 receptor agonist
A once-daily GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with a long clinical evidence base preceding semaglutide.
Overview
Liraglutide is a GLP-1 receptor agonist and one of the major clinical predecessors to semaglutide. It is administered once daily in regulated products for diabetes and weight-management indications.
The Science
Liraglutide activates GLP-1 receptors, producing glucose-dependent insulin secretion, reduced glucagon, slowed gastric emptying, and central appetite effects.
- Diabetes research - glycemic control and cardiometabolic endpoints.
- Weight management - appetite and energy-intake reduction.
- GLP-1 lineage - useful comparison point for semaglutide and newer incretin therapies.
Evidence Snapshot
Liraglutide has a substantial clinical evidence base. Research interest often focuses on how daily GLP-1 agonism compares with longer-acting weekly agents.
Related
More in Metabolic
Adipotide
Research compoundMetabolic
An experimental peptidomimetic studied preclinically for targeting adipose vasculature through prohibitin-related mechanisms, with major translational and safety uncertainty.
AICAR
Research compoundMetabolic
Not a peptideNucleotide analog
A nucleotide analog and AMPK-pathway research tool studied in cellular energy sensing, exercise-mimetic biology, cardiometabolic research, and anti-doping contexts.
AOD-9604
Research compoundMetabolic
A synthetic fragment of growth hormone designed to isolate GH's fat-mobilizing effects without its growth-promoting or blood-sugar-altering activity — a tool researchers and self-experimenters study for body composition and joint health.